Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells

Leukemia Research

Volumn 38, Issue 11, 2014, Pages 1299-1308

  Gul Uludağ, Hilal ^a   Valencia Serna, Juliana ^a   Kucharski, Cezary ^a   Marquez Curtis, Leah A ^b   Jiang, Xiaoyan ^c,d   Larratt, Loree ^a   Janowska Wieczorek, Anna ^a,b   Uludağ, Hasan ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Acute myeloid leukemia; CD44 receptor; Polymeric nanoparticle; SiRNA silencing

Indexed keywords

CD34 ANTIGEN; HERMES ANTIGEN; HYALURONIC ACID; NANOPARTICLE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; LYMPHOCYTE ANTIGEN RECEPTOR; POLYMER;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL ADHESION; CELL CULTURE; CELL INTERACTION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; KG 1 CELL LINE; KG 1A CELL LINE; MALE; MESENCHYMAL STEM CELL; MYELOID LEUKEMIA CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT; CELL DIFFERENTIATION; CHEMISTRY; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTIGENS, CD34; ANTIGENS, CD44; CELL DIFFERENTIATION; CELL LINE, TUMOR; GENE SILENCING; HUMANS; LEUKEMIA, MYELOID, ACUTE; NANOPARTICLES; POLYMERASE CHAIN REACTION; POLYMERS; RECEPTORS, ANTIGEN; RNA, SMALL INTERFERING;

EID: 84910083051     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.08.008     Document Type: Article

References (58)

1. Fröhling S., Scholl C., Gilliland D.G., Levine R.L. Genetics of myeloid malignancies: pathogenic and clinical implications. J Clin Oncol 2005, 23:6285-6295.
2. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
3. Burnett A. MRC trials in acute myeloblastic leukemia: where have we got to?. Leuk Lymphoma 2007, 48:2289-2290.
4. Ishikawa F., Yoshida S., Saito Y., Hijikata A., Kitamura H., Tanaka S., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007, 25:1315-1321.
5. Mikkola H.K., Radu C.G., Witte O.N. Targeting leukemia stem cells. Nat Biotechnol 2007, 28:237-238.
6. Konopleva M.Y., Jordan C.T. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011, 29:591-599.
7. Nwajei F., Konopleva M. The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol 2013, 953982.
8. Park I.K., Qian D., Kiel M., Becker M.W., Pihalja M., Weissman I.L., et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423:302-305.
9. Kato Y., Iwama A., Tadokoro Y., Shimoda K., Minoguchi M., Akira S., et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med 2005, 202:169-179.
10. Konopleva M., Tabe Y., Zeng Z., Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 2009, 12:103-113.
11. + stem/progenitor cells to bone marrow. Blood 2004, 103:2981-2989.
12. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
13. Krause D.S., Lazarides K., von Andrian U.H., Van Etten R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006, 12:1175-1180.
14. + cells. Leukemia 2000, 14:1239-1246.
15. Legras S., Gunthert U., Stauder R., Curt F., Oliferenko S., Kluin-Nelemans H.C., et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 1998, 91:3401-3413.
16. Quéré R., Andradottir S., Brun A.C., Zubarev R.A., Karlsson G., Olsson K., et al. High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event. Leukemia 2011, 25:515-526.
17. Harada H., Nakata T., Hirota-Takahata Y., Tanaka I., Nakajima M., Takahashi M. F-16438s, novel binding inhibitors of CD44 and hyaluronic acid. I. Establishment of an assay method and biological activity. J Antibiot (Tokyo) 2006, 59:770-776.
18. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23:1147-1157.
19. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010, 46:1271-1277.
20. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006, 6:714-727.
21. Hansel T.T., Kropshofer H., Singer T., Mitchell J.A., George A.J. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010, 9:325-338.
22. Fenske D.B., Cullis P.R. Liposomal nanomedicines. Expert Opin Drug Deliv 2008, 5:25-44.
23. Merritt W.M., Lin Y.G., Spannuth W.A., Fletcher M.S., Kamat A.A., Han L.Y., et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008, 100:359-372.
24. Egusquiaguirre S.P., Igartua M., Hernandez R.M., Pedraz J.L. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol 2012, 14:83-93.
25. Aliabadi H.M., Landry B., Bahadur R.K., Neamnark A., Suwantong O., Uludağ H. Impact of lipid substitution on assembly and delivery of siRNA by cationic polymers. Macromol Biosci 2011, 12:662-672.
26. Montazeri Aliabadi H., Landry B., Mahdipoor P., Uludağ H. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line. Mol Pharma 2011, 8:1821-1830.
27. Aliabadi H.M., Mahdipoor P., Uludağ H. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells. Cancer Gene Ther 2013, 20:169-177.
28. Subramaniam V., Vincent I.R., Gilakjan M., Jothy S. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol 2007, 83:332-340.
29. Li C.Z., Liu B., Wen Z.Q., Li H.Y. Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Folia Biol (Praha) 2008, 54:180-186.
30. Shah V., Taratula O., Garbuzenko O.B., Taratula O.R., Rodriguez-Rodriguez L., Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res 2013, 19:6193-6204.
31. Van Phuc P., Nhan P.L., Nhung T.H., Tam N.T., Hoang N.M., Tue V.G., et al. Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. Onco Targets Ther 2011, 4:71-78.
32. Cioca D.P., Aoki Y., Kiyosawa K. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 2003, 10:125-133.
33. Yang J.S., Hour M.J., Huang W.W., Lin K.L., Kuo S.C., Chung J.G. MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells. J Pharmacol Exp Ther 2010, 334:477-488.
34. Landry B., Aliabadi H.M., Samuel A., Gül-Uludağ H., Jiang X., Kutsch O., et al. Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines. PLoS ONE 2012, 7:e44197.
35. Pan J., Zou J., Wu D.Y., Roberson R.S., Hennings L.J., Ma X., et al. TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells. Mol Cancer Res 2008, 6:862-872.
36. Ling B., Zhou Y., Feng D., Shen G., Gao T., Shi Y., et al. Down-regulation of EDAG expression by retrovirus-mediated small interfering RNA inhibits the growth and IL-8 production of leukemia cells. Oncol Rep 2007, 18:659-664.
37. Papapetrou E.P., Zoumbos N.C., Athanassiadou A. Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects. Gene Ther 2005, 12:118-130.
38. He W., Bennett M.J., Luistro L., Carvajal D., Nevins T., Smith M., et al. Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability. Mol Ther 2014, 22:359-370.
39. Valencia-Serna J., Gul-Uludağ H., Mahdipoor P., Jiang X., Uludağ H. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation. J Control Release 2013, 172:495-503.
40. Gul H., Marquez-Curtis L.A., Jahroudi N., Larratt L.M., Janowska-Wieczorek A. Valproic acid exerts differential effects on CXCR4 expression in leukemic cells. Leuk Res 2010, 34:235-242.
41. Jiang H., Secretan C., Gao T., Bagnall K., Korbutt G., Lakey J., et al. The development of osteoblasts from stem cells to supplement fusion of the spine during surgery for AIS. Stud Health Technol Inform 2006, 123:467-472.
42. Li J., Zucker S., Pulkoski-Gross A., Kuscu C., Karaayvaz M., Ju J., et al. Conversion of stationary to invasive tumor initiating cells (TICs): role of hypoxia in membrane type 1-matrix metalloproteinase (MT1-MMP) trafficking. PLoS ONE 2012, 7:e38403.
43. Zepeda-Moreno A., Taubert I., Hellwig I., Hoang V., Pietsch L., Lakshmanan V.K., et al. Innovative method for quantification of cell-cell adhesion in 96-well plates. Cell Adh Migr 2011, 5:215-219.
44. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
45. + cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci USA 2002, 99:413-418.
46. Morimoto K., Robin E., Le Bousse-Kerdiles M.C., Li Y., Clay D., Jasmin C., et al. CD44 mediates hyaluronan binding by human myeloid KG-1A and KG-1 cells. Blood 1994, 83:657-662.
47. Gul-Uludag H., Xu P., Marquez-Curtis L.A., Xing J., Janowska-Wieczorek A., Chen J. Cationic liposome-mediated CXCR4 gene delivery into hematopoietic stem/progenitor cells: implications for clinical transplantation and gene therapy. Stem Cells Dev 2012, 21:1587-1596.
48. + phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat 2012, 133:979-995.
49. Jaggupilli A., Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012, 708036.
50. de Jong M.C., Pramana J., van der Wal J.E., Lacko M., Peutz-Kootstra C.J., de Jong J.M., et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 2010, 16:5329-5338.
51. Kawano T., Nakamura Y., Yanoma S., Kubota A., Furukawa M., Miyagi T., et al. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer. Auris Nasus Larynx 2004, 31:35-41.
52. Merlos-Suarez A., Barriga F.M., Jung P., Iglesias M., Céspedes M.V., Rossell D., et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8:511-524.
53. Miele E., Spinelli G.P., Miele E., Di Fabrizio E., Ferretti E., Tomao S., et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomed 2012, 7:3637-3657.
54. McClatchey K.D. Clinical laboratory medicine 2002, Lippincott Williams & Wilkins, Philadelphia, PA, USA. 2nd ed.
55. Holen T., Amarzguioui M., Wiiger M.T., Babaie E., Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucl Acids Res 2002, 30:1757-1766.
56. Cantini L., Attaway C.C., Butler B., Andino L.M., Sokolosky M.L., Jakymiw A. Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells. PLoS ONE 2013, 8:e73348.
57. Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., Markwald R.R., et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2011, 278:1429-1443.
58. Charrad R.S., Gadhoum Z., Qi J., Glachant A., Allouche M., Jasmin C., et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 2002, 99:290-299.